Theriva Biologics (TOVX) News Today $0.41 0.00 (-0.92%) Closing price 08/29/2025 04:10 PM EasternExtended Trading$0.41 0.00 (-0.49%) As of 08/29/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock TOVX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest UpdateAugust 22, 2025 | americanbankingnews.comTheriva Biologics, Inc.: Theriva Biologics Reports Second Quarter 2025 Operational Highlights and Financial ResultsAugust 12, 2025 | finanznachrichten.deTheriva Biologics Faces Financial Risks Amid Shifting Trade Policies and TariffsAugust 12, 2025 | msn.comTheriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial ResultsAugust 11, 2025 | globenewswire.comTheriva Biologics Sets 2025 Shareholder Meeting DateJune 25, 2025 | tipranks.comTheriva Biologics, Inc.: Theriva Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review ...May 29, 2025 | finanznachrichten.deTheriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the ...May 29, 2025 | morningstar.comMTheriva Biologics, Inc.: Theriva Biologics Reports First Quarter 2025 Operational Highlights and Financial ResultsMay 14, 2025 | finanznachrichten.deTheriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial ResultsMay 14, 2025 | globenewswire.comTheriva Biologics, Inc.: Theriva Biologics Announces Closing of $7.5 Million Public OfferingMay 9, 2025 | finanznachrichten.deTheriva Biologics Announces Pricing of Public Offering for $7.5 Million to Support Cancer Therapeutics DevelopmentMay 9, 2025 | nasdaq.comTheriva Biologics Announces Closing of $7.5 Million Public OfferingMay 8, 2025 | globenewswire.comTheriva Biologics, Inc.: Theriva Biologics Announces Pricing of $7.5 Million Public OfferingMay 7, 2025 | finanznachrichten.deTheriva Biologics Announces Pricing of $7.5 Million Public OfferingMay 7, 2025 | globenewswire.comTheriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant RecipientsApril 10, 2025 | globenewswire.comTheriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025April 2, 2025 | nasdaq.comTheriva Biologics says IDMC considers VCN-01 to be well toleratedApril 2, 2025 | markets.businessinsider.comTheriva Biologics to Present at the CAGLA NeauxCancer 2025 Conference in New OrleansMarch 21, 2025 | nasdaq.comTheriva™ Biologics to Present at the 2025 NeauxCancer ConferenceMarch 19, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Myomo (MYO) and Theriva Biologics (TOVX)March 12, 2025 | markets.businessinsider.comTheriva Biologics Reports 2024 Financial Results and ProgressMarch 7, 2025 | tipranks.comTheriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial ResultsMarch 6, 2025 | globenewswire.comTheriva™ Biologics to Participate in the Q1 Investor Summit VirtualMarch 5, 2025 | markets.businessinsider.comTherivaâ„¢ Biologics to Participate in the Q1 Investor Summit VirtualMarch 5, 2025 | globenewswire.comTheriva Biologics files to sell 7.69M shares of common stock, warrantsDecember 11, 2024 | markets.businessinsider.comTheriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic CancerDecember 5, 2024 | globenewswire.comTheriva Biologics Highlights Key Achievements in Q3 2024November 13, 2024 | tipranks.comTheriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial ResultsNovember 13, 2024 | markets.businessinsider.comTheriva Biologics, Inc.: Theriva Biologics Reports Third Quarter 2024 Operational Highlights and Financial ResultsNovember 12, 2024 | finanznachrichten.de3 Penny Stocks to Watch Now, 11/5/24November 5, 2024 | msn.comTheriva Biologics Expands Stock Plans and Share AuthorityNovember 2, 2024 | markets.businessinsider.comWhat's Going On With Theriva Biologics Stock Friday?November 2, 2024 | msn.comTheriva Biologics picked as finalist in competition for Merck KGaA’s EMEA grantNovember 1, 2024 | markets.businessinsider.comTheriva Biologics, Inc.: Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech GrantOctober 31, 2024 | finanznachrichten.deTheriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech GrantOctober 31, 2024 | markets.businessinsider.comTheriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of RetinoblastomaOctober 16, 2024 | globenewswire.comTheriva Biologics (AMEX:TOVX) Stock, Insider Trading ActivityOctober 4, 2024 | benzinga.comNano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant PatientsOctober 4, 2024 | finance.yahoo.comTheriva Biologics (AMEX:TOVX) Stock, Short Interest ReportSeptember 27, 2024 | benzinga.comTheriva Biologics dips 11%, prices 2.5M equity offeringSeptember 27, 2024 | msn.comTheriva Biologics Announces Pricing of $2.5 Million Public OfferingSeptember 26, 2024 | globenewswire.comTheriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic CancerSeptember 23, 2024 | globenewswire.comTheriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer ProgramSeptember 16, 2024 | markets.businessinsider.comTheriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer ProgramSeptember 16, 2024 | globenewswire.comTheriva Biologics (TOVX) Is Making Noise With a Promising PipelineSeptember 4, 2024 | msn.comTheriva Biologics (AMEX:TOVX) Stock Quotes, Forecast and News SummaryAugust 30, 2024 | benzinga.comWhat's Going On With Theriva Biologics Stock?August 30, 2024 | msn.comTheriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Significant Decline in Short InterestAugust 27, 2024 | marketbeat.comTheriva Biologics, Inc. (SFY.F)August 26, 2024 | nz.finance.yahoo.comWhat's Going On With Theriva Biologics (TOVX) Stock?August 20, 2024 | benzinga.com Get Theriva Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for TOVX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TOVX Media Mentions By Week TOVX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TOVX News Sentiment▼0.981.05▲Average Medical News Sentiment TOVX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TOVX Articles This Week▼00▲TOVX Articles Average Week Get the Latest News and Ratings for TOVX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Theriva Biologics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies LTUS News THAR News EDSA News HOTH News LPCN News XFOR News NRSN News AIMD News LIXT News BLRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:TOVX) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theriva Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theriva Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
